Abbott (ABT) Q2 2025: Medical Devices Surge 12% as Diagnostics Face $1B Headwind

July 17, 2025 | By EarningsIQ Research

Abbott’s diversified business model absorbed a $1 billion diagnostics headwind, with medical devices and branded generics driving high single-digit growth and margin expansion. Transitory challenges in China diagnostics and COVID testing mask underlying momentum across devices, biosimilars, and emerging markets. Management signals confidence in sustaining high single-digit growth and double-digit EPS as temporary pressures fade and new product launches accelerate in 2026.

Summary

• Medical Devices Outpace Expectations: Double-digit growth across diabetes, heart failure, and rhythm management offsets diagnostics drag.
• Diagnostics Headwinds Prove Transitory: China volume-based procurement and COVID declines weigh, but core lab strength persists outside China.
• 2026 Pipeline Momentum Builds: Management projects acceleration as biosimilars, dual-analyte sensors, and structural heart launches ramp.

Performance Analysis

Abbott’s Q2 results underscore the resilience of its diversified model, with medical devices (+12%) and branded generics (EPD, +8%) leading the portfolio. Diabetes care sales reached $1.9 billion, up 19.5%, fueled by global Libre adoption and momentum in all user segments. Adult nutrition and emerging markets also delivered steady growth, while diagnostics declined 1.5% due to the steep drop in COVID testing and persistent China procurement headwinds.

Gross and operating margins each expanded by 100 basis points year-over-year, reflecting scale leverage and disciplined SG&A. Currency impacts shifted to neutral for the full year, helping offset nearly $200 million in tariff costs. Adjusted EPS grew 11% year-over-year and 16% sequentially, even as over $1 billion in diagnostics headwinds and tariffs weighed on reported results.

• Device-Driven Growth: Double-digit gains in diabetes, EP, heart failure, and rhythm management signal strong execution and product cycle momentum.
• Diagnostics Drag: China VBP and COVID testing declines create a $1 billion revenue headwind, but core lab ex-China grew 8%.
• Margin Expansion: Gross and operating margins each rose 100 bps, aided by mix and cost control.

Abbott’s ability to deliver high single-digit growth and margin expansion despite sector-specific shocks highlights the durability of its business model. The company’s outlook for 2026 leans on pipeline launches and the dissipation of temporary headwinds.

Executive Commentary

Strategic Positioning

1. Medical Devices: Sustained Outperformance and Pipeline Depth

Medical devices remain Abbott’s growth engine, with broad-based double-digit gains across diabetes care, heart failure, structural heart, and rhythm management. Libre, Abbott’s CGM (continuous glucose monitor), continues to expand in all user segments, with new sensor innovation (dual-analyte for glucose/ketone) expected to further accelerate adoption. Electrophysiology (EP) and leadless pacemakers (AVERE) are capturing share, aided by new launches (Volt PFA catheter) and expanded clinical data. The company’s pipeline, including next-gen MitraClip and Tendine replacement valves, underpins confidence in sustained device-led growth.

2. Diagnostics: Navigating Transitory Headwinds

Diagnostics faced a $1 billion headwind from China volume-based procurement (VBP) and COVID testing declines, but core lab diagnostics ex-China grew 8%, and Alinity platform adoption remains robust. Management expects China’s volume recovery to shift into Q4, framing current pressures as temporary. U.S. and Europe core lab growth in the high single digits supports the view that underlying demand remains solid.

3. Emerging Markets and Branded Generics: Leveraging Demographic Trends

EPD (Established Pharmaceuticals Division) posted 8% growth, with “key 15” markets surpassing $1 billion in quarterly sales for the first time. Abbott’s focus on branded generics and biosimilars positions it to capture rising demand driven by an expanding middle class, aging populations, and increased healthcare access in Asia, Latin America, and the Middle East. The biosimilars pipeline, with 10 regulatory submissions and launches starting in 2026, is set to become a new growth vector.

4. Margin Management and Capital Allocation

Margin expansion was achieved despite tariff and FX headwinds, reflecting disciplined cost control and operational leverage. Abbott continues to invest in manufacturing flexibility (90 sites globally, new U.S. cardiovascular plant) to mitigate tariff risk and support future growth. M&A remains focused on diagnostics and devices, with management signaling a selective approach prioritizing strategic fit and return on invested capital.

5. Innovation and Product Launches Fueling 2026 Acceleration

Abbott’s 2026 outlook is anchored in a wave of product launches—including Volt (PFA catheter), dual-analyte CGM, new Alinity systems, and biosimilars. Management expects current diagnostics headwinds to fade, setting up for growth acceleration and margin leverage as new products scale.

Key Considerations

Abbott’s Q2 results reflect both the benefits and complexity of a broad-based healthcare portfolio. While device momentum and emerging market growth are robust, diagnostics headwinds and tariffs test management’s ability to deliver consistent results.

Key Considerations:

• Diagnostics Recovery Timing: China VBP and COVID testing headwinds are expected to wane, but the pace of volume recovery remains a watchpoint for 2025 exit and 2026 acceleration.
• Device Pipeline Execution: Sustained double-digit growth in diabetes and EP depends on successful new product launches and continued share gains.
• Biosimilars and Emerging Markets: The scale and speed of biosimilar uptake in key emerging markets will determine the next leg of EPD growth.
• Tariff and FX Management: Ongoing cost pressures require operational agility; manufacturing investments and global supply chain flexibility are critical to margin protection.
• M&A Selectivity: Abbott’s strong organic pipeline affords patience in deal-making, with diagnostics and devices as focus areas for potential bolt-ons.

Risks

Diagnostics headwinds from China VBP and COVID testing declines remain unpredictable in timing and magnitude, posing ongoing risk to near-term sales growth. Tariff costs and FX volatility continue to pressure margins, while pipeline execution and regulatory timelines for new launches represent potential sources of upside or downside. Litigation risk, particularly in nutrition, is being closely monitored but is not a material revenue driver at present.

Forward Outlook

For Q3 2025, Abbott guided to:

• Adjusted EPS of $1.28 to $1.32
• Reported sales growth aided by a 2% favorable FX impact

For full-year 2025, management reaffirmed guidance for:

• High single-digit organic sales growth (ex-COVID)
• Double-digit adjusted EPS growth

Management highlighted several factors that shape the outlook:

• Diagnostics headwinds are expected to moderate, with China recovery pushed to Q4.
• Device launches and biosimilars ramping in 2026 are expected to accelerate growth and margin leverage.

Takeaways

Abbott’s Q2 results reinforce the company’s ability to deliver growth and margin expansion through portfolio diversity and operational discipline.

• Device Momentum Offsets Diagnostics Drag: Leadership in diabetes, EP, and heart failure is driving outsized growth, while diagnostics awaits recovery.
• Pipeline and Emerging Markets Set Up 2026: New product launches and biosimilars are poised to drive the next growth wave as temporary headwinds fade.
• Investors Should Watch Diagnostics Recovery and Launch Cadence: The timing of China and COVID testing normalization, combined with execution on key launches, will be decisive for upside in 2026.

Conclusion

Abbott’s Q2 2025 demonstrated the strength and resilience of its diversified model, with medical devices and emerging markets absorbing diagnostics shocks. Management’s confidence in pipeline-driven acceleration and margin expansion sets a constructive tone for 2026, provided execution remains on track and transitory headwinds abate as expected.

Industry Read-Through

Abbott’s quarter offers a clear read-through for global medtech and diagnostics peers: device-led portfolios with deep pipelines are best positioned to offset macro and regional shocks, while diagnostics players exposed to China VBP and COVID normalization must brace for continued volatility. Emerging market branded generics and biosimilars are becoming increasingly material growth drivers, signaling opportunity for companies with established infrastructure and regulatory agility. Margin management and supply chain flexibility remain critical levers as tariffs and FX volatility persist across the sector.

ABT Healthcare Medical Devices Diagnostics Biosimilars Emerging Markets Tariffs